Cyclophilin B
Human Recombinant PPIB - His Tagged
Reference ID:KB-3903
Western Blot
Flow Cytometry
Gene of Interest
Gene Synonyms:PPIB;CYPB
Protein Names:Peptidyl-prolyl cis-trans isomerase B (PPIase B) (EC (CYP-S1) (Cyclophilin B) (Rotamase B) (S-cyclophilin) (SCYLP)
Accession Data
Organism:Homo sapiens (Human)
Mass (kDa):237.43
Length (aa):216
Proteomics (Proteome ID):UP000005640
Proteomics (Chromosome): Chromosome 15
Activity Regulation: Inhibited by cyclosporin A (CsA). {ECO:0000305|PubMed:20676357}.
Catalytic Activity: Reaction=[protein]-peptidylproline (omega=180) = [protein]-peptidylproline (omega=0); Xref=Rhea:RHEA:16237, Rhea:RHEA-COMP:10747, Rhea:RHEA-COMP:10748, ChEBI:CHEBI:83833, ChEBI:CHEBI:83834; EC=; Evidence={ECO:0000269|PubMed:20676357};
Function [CC]:PPIase that catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides and may therefore assist protein folding. {ECO:0000269|PubMed:20676357}.
Chemical Profile | ChEBI:peptidylproline (omega=0) residue [CHEBI:83833]; peptidylproline (omega=180) residue [CHEBI:83834]
ChEBI (Catalytic Activity):peptidylproline (omega=0) residue [CHEBI:83833]; peptidylproline (omega=180) residue [CHEBI:83834]
Disease:Osteogenesis imperfecta 9 (OI9) [MIM:259440]: A form of osteogenesis imperfecta, a connective tissue disorder characterized by low bone mass, bone fragility and susceptibility to fractures after minimal trauma. Disease severity ranges from very mild forms without fractures to intrauterine fractures and perinatal lethality. Extraskeletal manifestations, which affect a variable number of patients, are dentinogenesis imperfecta, hearing loss, and blue sclerae. OI9 is a severe autosomal recessive form of the disorder. {ECO:0000269|PubMed:19781681, ECO:0000269|PubMed:20089953}. Note=The disease is caused by mutations affecting the gene represented in this entry.
Mutagenesis:MUTAGEN 129 129 K->A: Impairs interaction with CLGN and CANX. {ECO:0000269|PubMed:20801878}.
Reagent Data
Name:Cyclophilin B
Region:Asp 34 - Ala 212
Molecular Weight:20.7
Purification System:Chromatography
Formulation:Sterile-filtered colorless solution
Formulation Concentration:1 mg/ml
Buffer Volume:Standard
Buffer Solution:PBS
Endotoxin Level:< 1%
Aggregate Tested By:SDS-PAGE
Endotoxin Screened:< 0.1 ng/ug
Purity:> 98%
Determined: SDS-PAGE
Validated: RP-HPLC
Sample Handling
Stability:This bioreagent is stable at 4°C (short-term) and -70°C(long-term). After reconstitution, sample may be stored at 4°C for 2-7 days and below -18°C for future use.
Preparation:Reconstitute in sterile distilled H2O to no less than 100 ug/ml; dilute reconstituted stock further in other aqueous solutions if needed. Please review COA for lot-specific instructions. Final measurements should be determined by the end-user for optimal performance.